Search Results

Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.

Sihuan Pharmaceutical Holdings Group Ltd. is pleased to announce that the “Group” was selected as one of the first echelon of enterprises in The list of China’s Top 100 Pharmaceutical Innovative Enterprises in 2023.

Qilian International Holding Group Limited, a China-based pharmaceutical and chemical products manufacturer, announced that an 1 for 5 reverse split of its authorized share capital, was approved by the Company’s board of directors on May 29, 2023 and will become effective on June 21, 2024.

Sihuan Pharmaceutical Holdings Group Ltd. together with its subsidiaries, is pleased to announce that Xuanzhu Biopharmaceutical Co., Ltd., a non-wholly owned subsidiary of Company, has received a drug registration approval from the National Medical Products Administration of China of Anaprozole Sodium Enteric-coated Tablet for the treatment of duodenal ulcer.

Pressure has been mounting for the Federal Trade Commission to take action, with Senator Elizabeth Warren last week urging FTC Chair Lina Khan to block the merger if it violates antitrust laws.

Sihuan Pharmaceutical Holdings Group Co., Ltd. is pleased to announce that the Group’s Jilin Huisheng Biopharmaceutical Co., Ltd., a non-wholly owned subsidiary, has successfully completed the acquisition of Jilin Baixing Bairong Investment Center *, JiLin Province Private Equity Co., Ltd., Jilin Province Technology Investment Fund Co., Ltd. in the A+ round of financing by way of capital increase.